NCT06008938 - An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

August 1, 2043

Study Completion Date

August 1, 2043

Conditions

Hemophilia B

Interventions

GENETIC

HEMGENIX

HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.

BIOLOGICAL

Factor IX (FIX)

FIX prophylaxis therapy

Trial Locations (9)

14604

RECRUITING

American Thrombosis and Hemostasis Network, Rochester

Unknown

RECRUITING

Medical University Vienna, Vienna

RECRUITING

Aarhus Universitetshospital, Århus N

RECRUITING

Centre Hospitalier Universitaire de Brest / CHU Morvan, Brest

RECRUITING

Centre Régional de Traitement de l'Hémophilie, Nantes

RECRUITING

CHU Nancy - Hôpital Brabois, Vandœuvre-lès-Nancy

RECRUITING

Klinik für Angiologie/ Hämostaseologie, Berlin

RECRUITING

Hannover Medical School, Hanover

RECRUITING

University Hospital Bern Inselspital, Bern